Search

Displaying results 4001 - 4010 of 5897 in total
  1. Drug

    Cagrilintide

    go.drugbank.com/drugs/DB18887
    Investigational

    Cagrilintide is under investigation in clinical trial NCT06221969 (A Research Study to See How Much Cagrisema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated

  2. Drug

    5-fluorotryptophan

    go.drugbank.com/drugs/DB03314
    Experimental

    5-fluorotryptophan can be used as substrate analogue to study enzyme mechanisms by NMR spectroscopy.

  3. Drug

    Uridine-5'-Diphosphate

    go.drugbank.com/drugs/DB03435
    Experimental

    A uracil nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety. [PubChem]

  4. Drug

    Zafiride

    go.drugbank.com/drugs/DB18371
    Investigational

    Zafiride is a human tumor necrosis factor coupled to the C terminus of CNGRCG peptide.

  5. Drug

    CoviGlobulin

    go.drugbank.com/drugs/DB15747
    Experimental

    The antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones. … Current applications of antibodies include, but are not limited to, targeting cancer, inflammatory diseases, organ transplantation, cardiovascular disease, infection, respiratory disease, and ophthalmologic

  6. Drug

    Alethine

    go.drugbank.com/drugs/DB05800
    Investigational

    It belongs to a family of chemicals called disulfides. It is a low molecular weight disulfide that has been shown to exhibit in vivo antitumor activity in murine myeloma and melanoma models.

  7. Drug

    Dihydroxyacetone

    go.drugbank.com/drugs/DB01775
    Experimental

    Its addition to blood preservation solutions results in better maintenance of 2,3-diphosphoglycerate levels during storage. … It is readily phosphorylated to dihydroxyacetone phosphate by triokinase in erythrocytes. In combination with naphthoquinones it acts as a sunscreening agent. [PubChem]

  8. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation

  9. Drug

    FT516

    go.drugbank.com/drugs/DB15732
    Investigational

    This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation.

  10. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073). … Phase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021.